Thinking about treatment with IMBRUVICA®?
Sign up today to receive the latest information and helpful resources.
In a clinical trial of 269 people, 8% of CLL patients on IMBRUVICA® (ibrutinib) died versus 16% taking a chemotherapy (chlorambucil), after 28 months of follow-up.1*
Here’s to more time together and the opportunity to keep doing what you love.
Here’s to saving on IMBRUVICA®
You may pay as little as $0 per prescription with the IMBRUVICA® Copay Card. Subject to eligibility; restrictions apply.†
Enroll Now
Receive one-on-one support plus financial and educational resources to help start and stay on track with IMBRUVICA®.‡
Explore Support Options
IMBRUVICA® for CLL
Questions to ask your doctor about CLL and IMBRUVICA®
Get More InformationAbout IMBRUVICA® for CLL
Learn from a patient
Real stories from CLL patients about their experience with IMBRUVICA®
View PatientVideos Here
In one clinical trial of 269 people aged 65 and older with CLL or SLL who had not been treated before, people who took IMBRUVICA® had a 56% lower risk of death compared to those taking a chemotherapy (chlorambucil). With a median follow-up of approximately 28 months, 8% of IMBRUVICA® patients died compared to 16% taking a chemotherapy.
Starting treatment is an important time in your journey with CLL/SLL. This website will help you learn more about your condition and how IMBRUVICA® can help.
IMBRUVICA® works differently from chemotherapy. This once-daily, oral medication blocks a protein in B cells called Bruton's tyrosine kinase, or BTK. For more complete information on how IMBRUVICA® works and the possible side effects, go to the How Does IMBRUVICA® Work? section.1
IMBRUVICA® is a prescription medicine used to treat adults with:
- Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
- Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion
It is not known if IMBRUVICA® is safe and effective in children.
From the moment you’re prescribed IMBRUVICA®, IMBRUVICA® By Your Side provides resources and support for getting the help you may need during treatment.
Coverage and Cost
Confirm your coverage and out-of-pocket costs for IMBRUVICA®.
IMBRUVICA® By Your Side
Registered Nurses
Call the By Your Side Nurse Support Line at 1-888-YourSide (1-888-968-7743) if you have questions about IMBRUVICA®.
†Eligibility: Available to patients with commercial insurance coverage for IMBRUVICA® (ibrutinib) who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit https://www.imbruvica.com/imbruvica-by-your-side or call 1-888-968-7743 for additional information. For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit https://www.pharmacyclics.com/privacy-notice.html#info_pcp.
‡IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have. By Your Side Registered Nurses are provided by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie Company, and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.
References: 1. IMBRUVICA® (ibrutinib) Prescribing Information. 2. National Institutes of Health. BTK gene. Accessed March 14, 2024. https://medlineplus.gov/genetics/gene/btk/